RE:RE:sale of animal health Zep, it's difficult to argue your analysis based on the performance of the former management.
This is what I heard at the AGM, if there is not a good offer (apparently there is a whisper number) on the table AH will not be sold. They would continue to push AH sales and introduce new product to increase sales, good will and ultimately value until a suitable offer is received. I am not convinced that Berendt is ready to part with AH until he completes his DD.
I was not surprised to hear that the FDA meeting in December was postponed, my guess is that for what ever reason our new CEO felt they were not ready for that step. The FDA meeting was a base runner from the previous regime; I am not holding Berendt responsible for that.
How about this theory?
Berendt has now had enough time to evaluate the operation and form a business plan. I really need to see something tangible happen by end of January.
- Will there be staff reduction,
- Can the VMC make money
- Partnerships for Urocidin with cash
- FDA Urocidin
- Animal Health - stay or go
- Econiche
- Oncocidin - Human
- More
Depending on how some of the above scenarios play out within a year we may see an all or nothing scenario in front of us. Will they put all of their focus on Urocidin? In my opinion if we see AH sell that’s the indicator that Berendt feels confident in Urocidin and the MCC platform. Game on from there.